MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/jamacardio.2026.1922

Медицинская библиотека · JAMA cardiology · 2026

Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-Analysis.

Zito Andrea, Landi Antonio, Bhatt Deepak L, Chen Shao-Liang, De Luca Giuseppe, Franzone Anna, Gwon Hyeon-Cheol, Kang Jeehoon, Hahn Joo-Yong, Hong Sung-Jin, Jang Yangsoo, Kim Byeong-Keuk, Kim Hyo-Soo, Kimura Takeshi, Mehran Roxana, Park Kyoung-Woo, Steg Philippe Gabriel, Stone Gregg W, Vranckx Pascal, Windecker Stephan, Valgimigli Marco

СтатьяСистематический обзорNetwork Meta-AnalysisПеревод в очереди

Аннотация

IMPORTANCE

The optimal duration of dual antiplatelet therapy (DAPT) in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) remains uncertain.

OBJECTIVES

To evaluate the safety and efficacy of abbreviated DAPT durations in patients at HBR undergoing PCI.

DATA SOURCES: PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched from inception to October 26, 2025.

STUDY SELECTION: Randomized clinical trials (RCTs) comparing abbreviated (ie, 1- to 3-month) vs standard (ie, 6- to 12-month) DAPT durations in patients at HBR without an indication for oral anticoagulation.

DATA EXTRACTION AND SYNTHESIS: A pairwise meta-analysis was performed to compare abbreviated (ie, 1-month to 3-month) vs standard (ie, ≥6-month) DAPT durations. A frequentist network meta-analysis was performed to compare 1-month, 3-month, and standard DAPT.

MAIN OUTCOMES AND MEASURES: The coprimary safety and efficacy end points were major or clinically relevant nonmajor bleeding (MCRB) and major adverse cardiovascular events (MACE; ie, a composite of cardiovascular death, myocardial infarction, or stroke).

RESULTS

A total of 14 RCTs encompassing 11 398 patients at HBR (mean [range] age, 74.7 [68.6-80.0] years; 39.1% female and 60.9% male) were included. Compared with standard DAPT, abbreviated DAPT was associated with lower MCRB (risk ratio [RR], 0.71; 95% CI, 0.55-0.92; P = .009) and major bleeding (RR, 0.76; 95% CI, 0.59-0.99; P = .04). The risks of MACE (RR, 0.97; 95% CI, 0.81-1.16; P = .76) and its individual components did not differ between abbreviated and standard regimens. An increased risk of MACE was observed with 1-month vs 3-month DAPT in the single trial comparing these regimens, but the network estimate was nonsignificant (RR, 1.28; 95% CI, 0.96-1.72).

CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, for patients at HBR undergoing PCI, abbreviated DAPT was associated with a lower risk of bleeding and, at least for 3-month regimens, was not associated with an increase in fatal or nonfatal ischemic cardiovascular or cerebrovascular events compared with standard 6- to 12-month DAPT.

Для цитирования: Zito Andrea, Landi Antonio, Bhatt Deepak L, Chen Shao-Liang, De Luca Giuseppe, Franzone Anna, Gwon Hyeon-Cheol, Kang Jeehoon, Hahn Joo-Yong, Hong Sung-Jin, Jang Yangsoo, Kim Byeong-Keuk, Kim Hyo-Soo, Kimura Takeshi, Mehran Roxana, Park Kyoung-Woo, Steg Philippe Gabriel, Stone Gregg W, Vranckx Pascal, Windecker Stephan, Valgimigli Marco. Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-Analysis.. JAMA cardiology. 2026. DOI: 10.1001/jamacardio.2026.1922.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.